Kymera Therapeutics

Inventing New Possibilities, Transforming Treatment Paradigms

Kymera Therapeutics is a biopharmaceutical company pioneering a transformative new modality, “targeted protein degradation” (TPD), with the ability to pursue targets long considered undruggable and to treat disease in entirely new ways. Its mission is to discover, develop and commercialize novel and transformative therapies to improve the lives of patients with serious diseases. Our team has developed a proprietary drug discovery engine, Pegasus, to enable the design of highly selective, small molecule protein degraders with potent activity against a broad range of disease indications. We are committed to selecting targets with the broadest possible impact across multiple disease indications with high unmet medical need to realize the full potential of TPD.

Kymera is led by an expert team of dedicated scientists and drug hunters, with decades of experience in the foundational areas of targeted protein degradation and drug development.

The Kymera Team

Management Team
Board Of Directors
Scientific Advisory Board
Academic Collaborators
Partners
Investors
Management Team
Management Team
Board Of Directors
Scientific Advisory Board
Academic Collaborators
Partners
Investors
Nello Mainolfi, PhD
Co-Founder, President and Chief Executive Officer
Read Bio
Nello Mainolfi, PhD
Co-Founder, President and Chief Executive Officer

Nello started his drug discovery career at the Novartis Institutes for Biomedical Research, leading teams to identify multiple novel potential medicines that have entered clinical development across a series of disease areas. Notably he led the team that discovered and developed the first complement factor B inhibitor now in late clinical development across a range of indications. Before founding Kymera, Mainolfi was an Entrepreneur in Residence at Atlas Venture and had previously led discovery research at cancer metabolism startup Raze Therapeutics. Nello has authored >60 papers and patents and has written reviews in the areas of medicinal chemistry, drug discovery and protein degradation. Nello was trained at Imperial College, University of London and The Scripps Research Institute in California.

Richard Chesworth, DPhil 
Chief Scientific Officer
Read Bio
Richard Chesworth, DPhil 
Chief Scientific Officer

Richard has more than 20 years of experience in the pharmaceutical and biotechnology industry and has contributed to the research and development programs of nine different compounds entering clinical trials including Tazverik™ which was recently approved for both epitheloid sarcoma and relapsed/refractory follicular lymphoma. Prior to joining Kymera as CSO, Richard was an Entrepreneur-In-Residence at Third Rock Ventures where he focused on building new drug discovery and development companies. Richard also served as Senior Vice President of Research at Epizyme, where he was responsible for pipeline activities from target selection to IND as well as non-clinical support of clinical candidates. Richard has also held positions at EnVivo (a.k.a. Forum Pharmaceuticals) Surface Logix, and, Pfizer. Richard obtained a BSc in Chemistry from Imperial College of Science, Technology and Medicine at the University of London and a DPhil in Chemistry from the University of Oxford.

Jared Gollob, MD
Chief Medical Officer
Read Bio
Jared Gollob, MD
Chief Medical Officer

In his role as CMO, Jared leads clinical development for Kymera Therapeutics, advancing clinical candidates identified by Kymera’s proprietary Pegasus™ targeted protein degradation platform. Jared joined Kymera from Alnylam Pharmaceuticals, where he was Vice President of Clinical Development and Global Vice President of Medical Affairs for Amyloidosis. There, he led early and late stage clinical programs in infectious disease, oncology, and amyloidosis that provided the first proof of concept in humans for RNA interference therapeutics and culminated in the FDA and EMA approvals of ONPATTROTM for the treatment of hereditary transthyretin amyloidosis. Jared previously held academic positions at Harvard Medical School and Duke University School of Medicine, and was on staff at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Duke University Medical Center, where he was engaged in both clinical and laboratory research in oncology and immunology. He has authored more than 50 peer-reviewed papers published in top-tier medical and scientific journals. Jared received his BA and MD from Columbia University, and completed clinical training in internal medicine and medical oncology at Massachusetts General Hospital and the Dana-Farber Cancer Institute, respectively.

Bruce Jacobs, CFA, MBA
Chief Financial Officer
Read Bio
Bruce Jacobs, CFA, MBA
Chief Financial Officer

As CFO, Bruce directs financial operations and investor relations for Kymera Therapeutics. Bruce joined Kymera with more than 25 years of experience in health care financial services, investment banking and equity research. He previously was Managing Partner for Westfield Capital Management, a Boston-based equity investment firm. In addition to his core portfolio management responsibilities, he served on the firm’s Management Committee and as the Health Care Team Lead. Bruce was also a Director with Alex Brown & Sons/Deutsche Bank and part of the health care investment banking group and the equity research team. He graduated magna cum laude from the Wharton School of the University of Pennsylvania, earned a Master of Business Administration from the Harvard Business School and is a Chartered Financial Analyst. Bruce is currently a member of the Board of Directors at Boys & Girls Clubs of Boston.

Brian Albarran, PhD, MBA
Vice President, Strategy and Operations
Read Bio
Brian Albarran, PhD, MBA
Vice President, Strategy and Operations

As Vice President, Strategy and Operations at Kymera Therapeutics, Brian is responsible for coordinating the cross-functional development and execution of Kymera’s R&D strategy, including oversight of the program/portfolio strategy and communications functions, and also supports long-range financial planning and business development. Brian joined Kymera from TESARO (now a GSK Company) where, as a Program Team Leader, he oversaw the FDA approval of rolapitant/Varubi and led multiple clinical programs in immuno-oncology, including the anti-PD-1 dostarlimab. While at TESARO, Brian also built and led the Competitive Intelligence function to support both clinical and commercial oncology programs, including niraparib/Zejula. Brian was previously a strategy consultant at Leerink and Navigant Consulting after numerous biotech roles in process development, manufacturing, and business development at ICOS, Trubion Pharmaceuticals, and Emergent BioSolutions. Brian earned his MBA from the Wharton School of Business and holds a PhD in Bioengineering from the University of Washington and a BSE in Biomedical Engineering from Duke University.

Paige Cochran
Vice President, Human Resources
Read Bio
Paige Cochran
Vice President, Human Resources

As Vice President of Human Resources at Kymera Therapeutics, Paige Cochran brings over 25 years of experience in human resources for both private and public high-growth companies across a variety of industries including biopharma, medical devices, clean technologies and other innovative technologies. She has previously served as VP of Human Resources at Microchips Biotech and Hydra Biosciences where she managed through critical phases of rapid company growth and organizational change. She brings to the team notable skills in executive coaching, employee relations, talent acquisition, compensation, performance management and compliance expertise. Paige holds a Bachelor’s degree in Psychology from Emory University.

Jeff Davis, MBA
Vice President, Head of Clinical Operations
Read Bio
Jeff Davis, MBA
Vice President, Head of Clinical Operations

As Vice President, Head of Clinical Operations at Kymera Therapeutics, Jeff is responsible for operational oversight and execution of all Kymera development programs. Jeff joined Kymera from FORMA Therapeutics where he performed a similar role of building out a development organization that scaled with the growing pipeline. Jeff has supported development programs focused in hematologic malignancies, blood and metabolic disorders. Prior to FORMA, Jeff helped oversee execution of the development programs and life cycle management for Iclusig® and Alunbrig® in CML and NSCLC, respectively. Jeff has also held similar positions at Biogen and Ziopharm Oncology. Jeff earned his MBA in Health Sector Management from Boston University and his BS in Biochemistry from Bates College.

Chris De Savi, PhD
Vice President, Head of Drug Discovery
Read Bio
Chris De Savi, PhD
Vice President, Head of Drug Discovery

As Vice President, Head of Drug Discovery at Kymera Therapeutics, Chris is responsible for medicinal and computational chemistry, lead discovery (biochemistry, biophysics, structural biology), pre-clinical development (DMPK and Toxicology) and proteomics. His team contributes to all drug discovery phases at Kymera from project inception through to clinical candidate discovery and beyond. Prior to joining Kymera, Chris was head of chemistry at Blueprint Medicines, a precision medicine company specialized in kinase drug discovery and development. Chris has deep experience in leading discovery research groups and project teams in both global pharmaceutical and biotech companies. He has directly contributed to the invention of 9 clinical candidate drugs for oncology and inflammation disease – most recently BLU-945, a EGFR T790M/C797S triple mutant inhibitor for the treatment of lung cancer, AZD4573, a selective CDK9 inhibitor for the treatment of haematological malignancies and AZD9496, an oral, selective estrogen receptor degrader for the treatment of ER+ breast cancer. He co-discovered Barasertib (AZD1152), a selective Inhibitor of Aurora B kinase for the treatment of AML. He is an author of over 50 peer-reviewed publications and patents in the fields of medicinal chemistry and drug discovery and a PhD qualified chemist who has previously held academic positions at Queens’ College Cambridge and University of Cambridge, Cambridge, UK.

Karen Martin, JD, PhD
Vice President, Head of Intellectual Property
Read Bio
Karen Martin, JD, PhD
Vice President, Head of Intellectual Property

As Vice President, Head of Intellectual Property at Kymera Therapeutics, Karen is responsible for all aspects of the company’s global intellectual property portfolio. Karen joined Kymera from Takeda Pharmaceuticals (formerly, Shire PLC), where she was Lead IP Counsel, US Business Unit, developing patent and trademark portfolios for assets in the oncology, ophthalmology, and rare disease space, in addition to supporting various post-grant, litigation, diligence, and transactional activities. Karen previously practiced intellectual property law at Wolf Greenfield & Sacks in Boston, MA, where she counseled clients in various technical areas including pharmaceuticals, diagnostics, polymers, sensors, and imaging technologies. Karen obtained her law degree from Suffolk University Law School and holds a PhD in Organic Chemistry from the Massachusetts Institute of Technology and a BS in Chemistry from Boston College.

Haojing Rong, PhD
Vice President, Preclinical Development
Read Bio
Haojing Rong, PhD
Vice President, Preclinical Development

Haojing is the Vice President of Preclinical Development at Kymera Therapeutics. Prior to joining Kymera in 2018, Haojing worked at Amgen, Merck, Amira Pharmaceuticals, Pfizer, and Shire. Haojing’s interest and expertise include ADME and Tox knowledge integration for both small molecule and biotherapeutics, prediction of human pharmacokinetics, drug interactions using modeling and simulation, and applying integrated PK/PD modeling approach for efficacy and safety in drug development. Haojing earned her PhD in Pharmaceutical Science at Ghent University in Belgium.

Anthony Slavin, PhD
Vice President, Immunology
Read Bio
Anthony Slavin, PhD
Vice President, Immunology

As Vice President, Immunology at Kymera Therapeutics, Anthony leads the Immunology team at Kymera Therapeutics and brings deep research and development experience in both small molecule and biologic drug discovery. He has been involved in multiple aspects of drug discovery and development in pharmaceutical and biotechnology companies in the U.S. for more than 20 years, leading discovery, and pharmacology teams, as well as being involved in efforts focused on the external identification and diligence of novel technologies and assets suitable for in-licensing and/or acquisition. Prior to joining Kymera, Anthony held leadership positions in Immunology at Abbvie and Boehringer Ingelheim, where he oversaw research departments dedicated to identifying and developing therapeutics for grievous autoimmune diseases, including the recently approved SKYRIZI, a monoclonal antibody targeting IL-23. He started his career at Tularik which was acquired by Amgen, and was a group leader at the Genomics Institute of the Novartis Research Foundation (GNF). Anthony holds a BSc (Hons.) and a PhD degree from the University of Melbourne and trained as a research fellow at Harvard Medical School and Stanford University.

Michael Todisco, MS
Vice President, Accounting & Finance
Read Bio
Michael Todisco, MS
Vice President, Accounting & Finance

As Vice President, Accounting & Finance at Kymera, Mike is responsible for all aspects of the company’s finance operations. Mike joined Kymera with over 25 years of experience, including 15 years in biotechnology. Mike was most recently Vice President Finance & Controller at Pear Therapeutics, and prior to that held Vice President positions at Karyopharm, Dicerna, BG Medicine and Dusa Pharmaceuticals. Earlier in his career, Mike spent time in public accounting with EY and KPMG in the audit practice. Mike obtained a BA in Economics from Colgate University and an MS in Accountancy from Northeastern University.

Nello Mainolfi, PhD
Co-Founder, President and Chief Executive Officer
Read Bio
Nello Mainolfi, PhD
Co-Founder, President and Chief Executive Officer

Nello started his drug discovery career at the Novartis Institutes for Biomedical Research, leading teams to identify multiple novel potential medicines that have entered clinical development across a series of disease areas. Notably he led the team that discovered and developed the first complement factor B inhibitor now in late clinical development across a range of indications. Before founding Kymera, Mainolfi was an Entrepreneur in Residence at Atlas Venture and had previously led discovery research at cancer metabolism startup Raze Therapeutics. Nello has authored >60 papers and patents and has written reviews in the areas of medicinal chemistry, drug discovery and protein degradation. Nello was trained at Imperial College, University of London and The Scripps Research Institute in California.

Bruce Booth, DPhil
Chairman and Co-Founder
Read Bio
Bruce Booth, DPhil
Chairman and Co-Founder

Bruce Booth is a partner and focuses on the discovery and development of novel medicines and therapeutic platforms.

Bruce is currently chairman of Arkuda Therapeutics, AvroBio (NASDAQ:AVRO), Hotspot Therapeutics, Kymera Therapeutics (NASDAQ:KYMR), Nimbus Therapeutics, and Quench Bio. He also serves on the board of Magenta Therapeutics (NASDAQ:MGTA) and several seed stage companies. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Lysosomal Therapeutics, miRagen (NASDAQ:MGEN), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Rodin Therapeutics (acquired by Alkermes), Stromedix (acquired by Biogen), Unum Therapeutics (NASDAQ:UMRX), and a number of other ventures.

Bruce serves or has served as an advisor in various capacities to Takeda, UCB, and the Gates Foundation. He also serves on the boards of the Pennsylvania State Research Foundation, which helps with technology transfer for Penn State, and New England Disabled Sports, a charity dedicated to adaptive sports. Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes.

Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a DPhil (PhD) in molecular immunology from Oxford University. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.

Bruce enjoys running, skiing, hiking, and fly fishing. He lives in Wellesley, MA and has three wonderful kids.

Jeff Albers, JD, MBA
Read Bio
Jeff Albers, JD, MBA

Jeff Albers has more than 15 years of experience bringing important new medicines to patients with cancer and rare diseases in leadership roles in the biopharmaceutical industry. In 2014, he joined Blueprint Medicines as Chief Executive Officer and member of the board of directors and led the research-stage company through an initial public offering. Since that time, Blueprint Medicines has evolved into a leading precision medicine company with a global, fully integrated business, including one FDA-approved therapy and a rapidly advancing pipeline. Jeff previously served as President of Algeta, where he oversaw the successful commercial launch of a targeted cancer therapy prior to the company’s acquisition by Bayer. Prior to Algeta, he held senior commercial and corporate development positions at Genzyme (now a division of Sanofi), most recently as vice president of the U.S. hematology and oncology business unit. Earlier in his career, Jeff was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo. He currently serves on the board of directors at Magenta Therapeutics and the Eastern New England Chapter of the American Cancer Society and is on the Board of Advisors for Life Sciences Cares. He holds a BS from Indiana University and an MBA and JD from Georgetown University.

Pamela Esposito, PhD
Read Bio
Pamela Esposito, PhD

Pamela L. Esposito, PhD is currently the Chief Business Officer of Replimune (NASDAQ REPL). Since its inception, Pamela has been responsible for both corporate and business development, having raised over $400M. Over the past 18 years, Pamela has held a variety of strategy, commercial and business development positions in small biotech companies, playing lead roles in transformative deals for each company. Previously, she was Chief Business Officer at Ra Pharmaceuticals (NASDAQ RARX). As an early member of Ra’s senior management team, Pamela played a leadership role in strategy, helping Ra transform from a discovery platform to a clinical stage company and raising approximately $58 million in a Series B mezzanine funding round. Prior to Ra, she was VP of Business Development at Biovex and led the negotiation of the acquisition of the company by Amgen. Early in her career, she was a director at Bioduro based in Beijing, China and Vion Pharmaceuticals in New Haven, CT. Currently, Pamela sits on the board of directors of Accent Therapeutics. Pamela earned a PhD in pharmacology from Tufts University School of Medicine and a BA from Dartmouth College.

Steve Hall, PhD
Read Bio
Steve Hall, PhD

Steve is a General Partner at Lilly Ventures and has more than 25 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations. Prior to joining Lilly Ventures, Steve was SVP of R&D at Serenex, Inc., where he was also a co-founder. He also has held operational and leadership roles at Eli Lilly, Sphinx Pharmaceuticals, and Bristol-Myers Squibb in the areas of oncology, cardiovascular disease, and lead generation technologies. Steve currently sits on the boards of Cavio Pharma, Esanex, FORMA Therapeutics, Hydra Biosciences, Lysosomal Therapeutics and Nimbus Therapeutics. Steve is the author of more than 40 papers and 60 patents. He received his BS in chemistry from Central Michigan University and his PhD in organic chemistry from Massachusetts Institute of Technology.

Andrew Hedin, MBA
Read Bio
Andrew Hedin, MBA

Andrew Hedin is an investor in Bessemer’s Cambridge office where he focuses on investments in healthcare.  Prior to joining Bessemer in 2015, Andrew worked at F-Prime Capital, Fidelity’s healthcare-focused venture capital fund, where he invested broadly across life sciences and healthcare technology, and he has also spent time with Leerink Partners.

He earned an MBA with honors from The Wharton School, where he majored in health care management and finance, as well as a degree in biological basis of behavior from the University of Pennsylvania.

Joanna Horobin, MB, ChB
Read Bio
Joanna Horobin, MB, ChB

Joanna Horobin, MB, ChB, is the former Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals, Inc. Prior to joining Idera in November 2015, Dr. Horobin was most recently the Chief Medical Officer of Verastem, Inc. and previously served as Chief Executive Officer of Syndax Pharmaceuticals.  Additionally, Dr. Horobin held several roles of increasing responsibility at global pharmaceutical corporations such as Rhône-Poulenc Rorer (now Sanofi) where she spearheaded the launch of the global Oncology business unit which included the commercial introduction of Taxotere® (docetaxel) in breast cancer and Campto/Camptosar® (CPT11) for colorectal cancer.  Dr. Horobin also led a successful joint venture with Chugai to launch Granocyte® (lenograstim).  Prior, Dr. Horobin played significant leadership roles in the approvals of Lovenox®, Celectol®, Augmentin®, Timentin®, temocillin, Bactroban® and Relafen®/Reliflex®.

Dr. Horobin currently serves as a Non-Executive Director of Nordic Nanovector ASA. Dr. Horobin received her medical degree from the University of Manchester, United Kingdom.

Gorjan Hrustanovic, PhD
Read Bio
Gorjan Hrustanovic, PhD

Dr. Gorjan Hrustanovic is a Principal at BVF Partners L.P., where he focuses on biotech and therapeutic investments. Gorjan is currently serving on the board of Rain Therapeutics, Inc., Olema Pharmaceuticals, Inc, and is also a board observer at 4D Molecular Therapeutics.

Prior to joining BVF in 2015, Gorjan received his PhD in Cancer Biology & Cell Signaling at the University of California, San Francisco (UCSF), where he also co-founded a small biotech-focused investment fund. At UCSF, his research focus was personalized medicine and molecularly targeted therapy in non-small cell lung cancer. His research in cancer biology is published in peer-reviewed journals such as Nature Medicine, Oncogene, Cell Reports, and others. Gorjan earned his BS degree in Molecular Biology, and a BS in Economics/Management Science from UCSD.

Donald W. Nicholson, PhD
Read Bio
Donald W. Nicholson, PhD

Dr. Don Nicholson is the former Chief Executive Officer of Nimbus Therapeutics. He joined from Merck, where he held various strategic, leadership and operational roles in diverse therapeutic areas, including respiratory, inflammation, immunology, bone, endocrine, urology, infectious disease and neurosciences. He began his career in 1998 at the Merck-Frosst Centre for Therapeutic Research in Montreal and advanced through various positions of increasing responsibility including Vice President & Site Head of the Merck Neurosciences Research site in San Diego, and most recently as Vice President and Worldwide Discovery Head for the Respiratory & Immunology Franchise, based in Kenilworth, N.J. Don has co-authored more than 150 publications in peer-reviewed scientific and medical journals and is internationally recognized for his contributions to the field of apoptotic cell death. He received his PhD. and an Honors BSc. degree in Biochemistry from the University of Western Ontario, and trained as a Medical Research Council postdoctoral fellow at the University of Munich in Germany. He is the recipient of multiple academic and professional honors.

Senior Director of Proteomics, Broad Institute
Professor, Rockefeller University and Investigator, Howard Hughes Medical Institute
Associate Professor, Oncology, Dana-Farber Cancer Institute
Chief Scientific Officer, Bicycle Therapeutics
American Cancer Society Professor and Director of the Center for Lymphoid Malignancies, Columbia University
Chair, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine and Investigator, Howard Hughes Medical Institute
Professor of General Pathology, Humanitas Clinical and Research Center
Professor of Chemistry, Yale University
Professor, Rheumatology, University of California San Diego
Professor of Pharmacology, University of Washington and Investigator, Howard Hughes Medical Institute